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Abstract
The interaction between sleep and primary headaches has gained considerable interest due to their strong, bidirectional,
clinical relationship. Several primary headaches demonstrate either a circadian/circannual rhythmicity in attack onset or
are directly associated with sleep itself. Migraine and cluster headache both show distinct attack patterns and while the
underlying mechanisms of this circadian variation in attack onset remain to be fully explored, recent evidence points to
clear physiological, anatomical and genetic points of convergence. The hypothalamus has emerged as a key brain area in
several headache disorders including migraine and cluster headache. It is involved in homeostatic regulation, including
pain processing and sleep regulation, enabling appropriate physiological responses to diverse stimuli. It is also a key
integrator of circadian entrainment to light, in part regulated by pituitary adenylate cyclase-activating peptide (PACAP).
With its established role in experimental headache research the peptide has been extensively studied in relation to
headache in both humans and animals, however, there are only few studies investigating its effect on sleep in humans.
Given its prominent role in circadian entrainment, established in preclinical research, and the ability of exogenous PACAP
to trigger attacks experimentally, further research is very much warranted. The current review will focus on the role of the
hypothalamus in the regulation of sleep-wake and circadian rhythms and provide suggestions for the future direction of
such research, with a particular focus on PACAP.
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Background
Primary headache disorders represent a group of diverse
neurological attack forms that present with varying
intensity, duration, frequency and associated symptoms
[1]. Despite these underlying differences the hypothal-
amus has emerged as a critical component of several
attack forms, including migraine [2–5] and cluster
headache [6–8]. The hypothalamus is a key regulator
of homeostatic mechanisms including sleep-wake
cycles that are under circadian regulation [9]. Given
the circadian and circannual nature of several attack
forms [10–12], the clinical association with sleep
disturbances [13, 14] and neuroimaging data suppor-
ting abnormal hypothalamic activation in several pri-
mary headache disorders [2, 4–6, 8, 15] there is an
unmet need to develop novel mechanistic insight that
may herald novel therapeutic strategies. In particular pitu-
itary adenylate cyclase-activating peptide (PACAP) has
emerged as a key neuropeptide involved in migraines and,
as a parasympathetic and hypothalamic signaling
molecule, that may be involved in cluster headache.
PACAP is known to trigger migraine [16, 17] in suscep-
tible individuals, plays a key role in hypothalamic circa-
dian entrainment to light [18] and is the subject of
significant interest as a potential therapeutic target for mi-
graine and cluster headache [19, 20]. As such, the current
review will focus on the potential regulation of sleep and
circadian mechanisms in primary headache disorders with
a particular focus on the regulation and future therapeutic
potential of modulating PACAP signaling.
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Introduction
The ability to adapt to external environmental condi-
tions is a fundamental principle for the survival of an
organism. As such several systems have evolved that per-
mit homeostatic regulation to internal and external cues,
facilitating appropriate physiological responses. These
are most evident in the daily regulation of sleep-wake
cycles with its circa 24-h rhythmicity (circadian), but
also include circannual (yearly), infradian (> day) and ul-
tradian (< day, but > one hour) rhythms. Sleep itself is
generally dissected into wakefulness, non-rapid eye
movement (NREM), and paradoxical or rapid eye move-
ment (REM) sleep. Encephalographically, REM sleep and
wakefulness are indistinguishable with fast, low ampli-
tude, desynchronized oscillations, whereas NREM sleep
stages I-III are characterized by increasingly lower fre-
quencies of synchronized cortical activity. The different
stages of sleep are precisely regulated, complex mecha-
nisms ensuring their consolidation at specific times (for
review see [21]), timely progression and avoidance of
intermediary stages.
While a complete understanding of the function of
sleep remains to be fully characterized it clearly has a
restorative effect on the brain [22]. It is proposed to be
regulated by at least two divergent mechanisms inclu-
ding circadian and homeostatic sleep pressure. This ele-
gant regulatory mechanism allows the body to respond
to “sleep need” via the accumulation of an endogenous
somnogens (e.g. Adenosine) on the background of a
circadian influence that entrains sleep-wake cycles to
external cues such as seasonal light-dark patterns, for re-
view see [9]. The neuroanatomical basis for sleep was
initially postulated in response to a wave of “encephalitis
lethargica” with the neurologist Von Economo detailing
the presence of lesions in the border of the midbrain
and diencephalon responsible for this excessive sleepi-
ness [23] and thus forming the basis for our current
understanding of arousal networks (see Fig. 1).
Complimentary observations in patients presenting with
insomnia highlighted lesions within the lateral hypothal-
amic area, with subsequent studies identifying specific
cell groups including the ventrolateral preoptic area
(VLPO) that act to promote sleep [24] and inhibit
arousal networks [25]. A further seismic step in our un-
derstanding of the regulation of sleep-wake cycles came
with the proposal of a “flip-flop” switch; whereby hypo-
thalamic orexinergic synthesizing neurons act to




Fig. 1 Mechanisms regulating sleep wake modulation. a. Orexinergic neurons originating in the lateral hypothalamus (LH; Green) send excitatory projections
to several brainstem nuclei that act to promote arousal. Ascending monoaminergic projections (purple) from the noradrenergic locus coeruleus (LC),
glutamaterigic parabrachial (PB) and pedunculopontine (PPT), serotoninergic dorsal raphe (DR), dopaminergic ventral periaqueductal grey (vPAG),
tuberomammillary nuceus (TMN) and GABAergic and cholinergic neurons in the basal forebrain (BF) diffusely innervate the cerebral cortex to promote
arousal. There are also cholinergic projections (Blue) from the laterodorsal tegmental nuclei (LDT) and PPT nuclei that project to the thalamus to promote
arousal. b. GABAergic ventrolateral preoptic (VLPO) neurons (Brown) act to inhibit the majority of the arousal nuclei, including LH orexinergic neurons to
promote sleep. c. Homeostatic sleep pressure (Blue line) increases through wakefulness, likely via the accumulation of endogenous somnogens such as
adenosine that excites VLPO neurons to promote sleep. This is combined with circadian sleep regulation (Red line) to create a balanced sleep wake cycle
that is entrained to external environmental conditions. The circadian component is in part dependent on pituitary adenylate cyclase-activating peptide
signalling within the hypothalamic suprachiasmatic nucleus as demonstrated by preclinical research
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wakefulness and are reciprocally inhibited in conjunction
with the ascending arousal nuclei by the VLPO during
sleep [26]. The importance of these neurons in the
regulation of arousal is evident in the devastating conse-
quences their loss has on patients suffering from narco-
lepsy [27].
Given the complex clinical relationship between circa-
dian/sleep regulation and headache, their shared physio-
logical and neuroanatomical basis (see Fig. 1 and reviewed
in [9, 28]), the emerging role for the hypothalamus in the
regulation of migraine and cluster headache-relevant
homeostatic regulation (see [9, 28]) and the emergence of
pituitary adenylate cyclase-activating peptide (PACAP) as
a key neuropeptide in the regulation of migraine biology
[20]. The current review will focus on the role of the
hypothalamus in the regulation of sleep-wake and circa-
dian rhythms, with a particular focus on PACAP.
PACAP
A detailed description of PACAP pharmacology is
discussed elsewhere in this special issue and in several
recent reviews including [29]. Herein we provide a brief
review for orientation purposes. PACAP is widely dis-
tributed throughout the peripheral and central nervous
system [30]. It occurs in two forms, PACAP-38 and
PACAP-27 that are cleaved from the same preproPA-
CAP protein. It is closely related to several neuropep-
tides including vasoactive intestinal peptide (VIP) and
peptide histadine methionine. Interestingly, VIP induces
a similar headache [31] to PACAP [32] in healthy volun-
teers, but fails to induce a delayed migraine-like attack
[31, 33]. PACAP and VIP share relatively equal affinity
for the VPAC1 and VPAC2 receptors, whereas PACAP
shows a greater affinity for the PAC1 receptor (for review
see [34]). As such, despite sharing similar signalling
mechanisms the PAC1 receptor has emerged as the first
PACAP receptor to be targeted clinically for migraines
[19]. This is supported by preclinical evidence suggesting
that PACAP, but not VIP [35] sensitizes trigeminal neu-
rons, an effect that was blocked by PAC1 antagonism.
In support of an emerging role for PACAP signalling
in headaches PACAP-38 concentrations have been
shown to be elevated during migraine attacks [36, 37]
and decreased interictally in episodic cluster headache,
with subsequent increases in bout [38]. With an
increased genetic understanding of migraine and the
identification of multiple susceptibility loci [39], it is
somewhat surprising that linkages to novel effective
pharmacological targets such as CGRP [40–42] or its re-
ceptor are not identified. As such it is less surprising
that there is no identified association between PACAP
or PAC1 signalling in migraine. In comparison, a
genome-wide association has been demonstrated for
PACAP in cluster headache [43].
Sleep and circadian rhythms in headache
The interaction between sleep and headache has gained
considerable interest due to a strong but complex clin-
ical relationship. This is evidenced from clinical and
population studies demonstrating a high penetrance of
sleep problems or manifest sleep disorders in headache
[44] and an ever increasing number of sophisticated
sleep studies [45–47] that point to several major points
of physiological and neuroanatomical overlap (for review
see [9, 28]).
In agreement with a role for sleep disruption in
headaches cluster headache (CH) patients complain of
reduced sleep amount – that is complicated by the pres-
ence of consistent nocturnal attacks that may directly
disrupt sleep. However; CH patients demonstrate poor
sleep quality both in- and outside of active cluster bouts
[10] highlighting a potential underlying disruption of
sleep homeostatic regulatory mechanisms separate from
the influence of the nocturnal attacks. This is further
supported by a high prevalence of sleep apnea [46], con-
founded by several overlapping risk factors – e.g. male
gender, high body mass index, smoking, and specific
sleep-linked attack forms, including hypnic headache [48].
The chronobiological nature of several headaches fur-
ther highlights a key circadian/circannual component to
attack onset, whilst ultradian components have not been
widely explored. The most prominent rhythmical head-
ache disorder is CH with its clear circadian [10–12]
(commonly during the early night) and circannual
periodicity - peak bout incidence potentially related to
summer and winter solstice [49]. This is the time of year
when the difference between night and day is greatest,
and in a modern setting, perhaps places the greatest
stress on homeostatic entrainment mechanisms. There-
fore, it could be postulated that a suboptimal function-
ing of the gain control in the light-governed entrainment
system could induce dysfunctional hypothalamic homeo-
static mechanisms [3], leading in turn to increased at-
tack propensity. Migraine on the other hand is most
commonly reported to initiate in the early hours of the
morning [50] with evidence of a circannual periodicity
linked to the light season with fewer attacks during the
dark season [51]. This would suggest that CH attacks
largely initiate during the early hours of sleep occurring
in two common phases – associated with altered envi-
ronmental light levels and migraine attacks largely initi-
ate during the last hours of sleep/early in the arousal
phase occurring most commonly in a single phase – as-
sociated with higher environmental light levels. It has
been suggested that such nocturnal headache attacks are
linked to specific macro-sleep phenomena [52]. While
this has not been completely refuted, evidence is limited
[45, 47] and recent research has suggested that noctur-
nal attacks may be linked to the cycling between sleep
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stages, and not to a particular stage itself [10]. This
theory of heightened attack susceptibility during the
transitioning from one state to another may give
important clues as to the potential mechanisms that
underlie attack initiation. For example, the presence
of excessive yawning [53] during migraine premoni-
tory symptoms points to a potential excess dopamin-
ergic tone [54]; however, the subsequent transition to
headache would be more likely associated with a
decreased dopaminergic tone – as dopamine has been
shown to be anti-nociceptive at least at the level of
the trigeminocervical complex [55, 56].
Traditionally, and due to technical limitations, enceph-
alographic analysis of sleep has been limited to
macrostrutural analysis of stage composition. However,
increasingly sophisticated analysis methods have
revealed changes in the microstructure of sleep. Such
analysis of sleep has revealed some interesting changes
in headache patients including migraine and CH.
Arousals are abrupt changes in EEG frequency of less
than 3 s duration. Such arousal phenomena are a part of
normal sleep and an increasing number are seen with
age. They indicate cortical activation and are generated
by systems in the basal forebrain, thalamus, hypothal-
amus and brainstem via ascending projections. In a
population especially prone to poor sleep quality one
would expect a high number of arousals, however,
counterintuitively, in both migraine and cluster
headache a reduced number of arousals have been found
[45, 57–59], suggesting that dysfunctional CNS neural
networks including hypothalamic, thalamic and brain-
stem nuclei may be a common feature.
PACAP in the regulation of sleep
As discussed above the ability to adapt to external
environmental conditions is a fundamental principle for
the survival of an organism. This allows for seasonal
variations in physiology and behavior that optimize our
interactions with the local environment. Additionally, as
the human intrinsic (“free-running”) circadian period is
24.1 h [60] the ability to entrain the “master clock” in
the hypothalamic suprachiasmatic nucleus (SCN) to
seasonal light-dark cycles ensures alignment to the
astronomical day. The SCN in turn acts as the central
circadian regulator ensuring that peripheral oscillators
(“local clocks”) regulating local cellular rhythms are syn-
chronized in part via regulation of specific brain circuits
[61]. This includes the regulation of the autonomic
nervous system [62] that controls peripheral tissue and
the rhythmic release of hormones including melatonin
from the pineal gland [63] that both entrains local
oscillators and inhibits SCN neuronal activity [64] in a
negative feedback manner.
Under normal conditions the rhythm of the SCN
is primarily influenced by light-dark cycles, with
light acting as the prominent “zeitgeber” in both di-
urnal and nocturnal animals. While common photo-
receptors such as rods and cones are involved in
light-entrainment non-image forming intrinsically
photosensitive retinal ganglion cells (ipRGCs) that
express melanopsin encoded by the Opn4 gene play
a prominent role [65]. In general, direct projections
from light-responsive ipRGCs synapse on SCN neu-
rons giving rise to the retinohypothalamic tract
(RHT), with additional sparse projections to other
hypothalamic nuclei. Additionally, indirect projec-
tions exist via the thalamic intergeniculate leaflet
that receives light-sensitive inputs and sends neuro-
peptide Y projections to the SCN. Early studies in
rodents highlighted the presence of PACAP immu-
noreactivity in a subset of RHT retinal ganglion cells
that were responsive to light and projected to the
SCN [66]. Later these PACAP containing neurons
were shown to express melanopsin and while
glutamate has been proposed as the main neuro-
transmitter in the RHT the role of PACAP is an
interesting issue with respect to headache disorders.
Peripherally administered PACAP is an established
experimental tool for the induction of migraine [33].
Both PACAP-38 and PACAP-27 potentially cross the
blood brain barrier (BBB) in a saturable and non-
saturable manner respectively [67, 68], although this
is not supported by human studies [32]. The pineal
gland lies outside the BBB and is innervated with
PACAP immunoreactive fibres that may in part arise
from the trigeminal ganglion [69]. Within the pineal
gland but not the pituitary PACAP levels show a cir-
cadian expression [70] that is phase dependent –
with the highest levels occurring during the dark
phase in rats. Given that PACAP can stimulate mela-
tonin synthesis [71, 72] and the lack of a functional
BBB, intravenous PACAP could, at least in theory,
modulate sleep-wake cycles via a direct action on
melatonin release. In agreement PACAP administra-
tion in rats increased the duration of REM sleep
[73]; however, PACAP-38 [74] administration in
healthy controls had no impact on the time spent in
each sleep stage, but did modulate slow wave sleep.
The inconsistency between the current clinical and
preclinical data in response to PACAP administra-
tion is complex, given likely differences in BBB
penetrability and the known dose-dependent oppos-
ing actions of PACAP on the SCN.
PACAP in the SCN
Circadian phases are regulated at the level of the
SCN by cell-autonomous, transcription translation
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feedback loops, whereby Period and Cryptochrome
gene expression is inhibited by their respective pro-
teins. The RHT sends light-sensitive projections to
multiple regions of the SCN [75] that signal via
glutamate [76], aspartate [77] and PACAP [18], as
well as indirect projections that utilize NPY [78] and
GABA [79] as the key neurotransmitters (for review
see [61]). Electrical stimulation of the RHT releases
glutamate [80] that induces phase responses and
inhibition of glutamatergic signaling blocks SCN re-
sponses to light pulses [81] establishing glutamate as
the prominent RHT – SCN neurotransmitter. While
direct evidence for PACAP release in the SCN is
limited, local application of PACAP [66, 82] in-vitro
was shown to phase advance SCN neurons during the
subjective day via a PAC1 dependent mechanism, but not
at night, suggesting a role for PACAP in daytime regula-
tion of the circadian cycle. During the subjective late night
co-administration of PACAP and glutamate blocks the
normal response to glutamate [83, 84], while inhibition of
PACAP signalling modulates this response, that was
supported by the ability of PACAP to potentiate glutamate
induced light responses in-vivo [83]. Conversely, during
the early night PACAP potentiated glutamate induced
phase delays that was inhibited by blocking PACAP
signalling [83]. As such PACAP may act to provide a gain
control mechanism for glutamate induced phase shifts
that could have a significant determinant on multiple
downstream peripheral oscillators [85]. This role of
PACAP is further supported by the use of available
PACAP or PAC1 knock-out mice that maintain a stable
activity-rest pattern during constant darkness and demon-
strate stable expression of clock genes. Despite this
apparently normal circadian phenotype PAC1 deficient
mice demonstrate impaired photic entrainment in agree-
ment with the above pharmacological data [86, 87] and
disrupted circadian food anticipatory behaviours [88].
The proposed mechanism of PACAP and glutamate
induced phase alterations is via the light sensitive
clock genes, Period 1 (per1) and Period 2 (per2) [84].
Ex-vivo glutamate administration on SCN brain
slices induces robust increases in per1 and per2 ex-
pressions; however, micromolar concentrations of
PACAP alone was unable to modulate their expres-
sion. In agreement with a role for PACAP as a
modulator, pre-administration of micromolar concen-
trations of PACAP completely blocked the effect of
glutamate, whilst nanomolar concentrations induced
per1 and per2 expression [84]. While data on the
role of specific clock genes in headache are limited
the recent discovery of human mutation in the cata-
lytic domain of the gene encoding casein kinase 1δ
(CK1δ; CK1δ-T44A) that was associated with both
familial advanced sleep phase syndrome (FASPS) and
migraine with aura [89]. Importantly phosphorylation
of PER proteins by CK1 proteins regulates the speed
of the circadian clock [90]. PER1 and PER2 are
phosphorylated at multiple sites by CK1δ and CK1ε
that facilitates their degradation and subsequent re-
lease of inhibitory repression of Clock/BMAL1 as
key elements of the cell-autonomous transcription
translation feedback loops [91, 92]. Thus this loss of
function mutation that co-expresses altered circadian
phases and migraine with aura indirectly highlight a
potential relationship between PER2 regulation and
migraine. With respect to CH several studies have
explored potential relationships with clock gene vari-
ants due to the striking circadian and circannual
periodicity of attacks. While no association has been
found between CH and per3 or the T-C Clock gene
polymorphism [93, 94] a recent publication deter-
mined a potential association between the
rs12649507 Clock gene polymorphism [95] that has
been previously associated with sleep duration [96].
Patients with the rs12649507 AA genotype addition-
ally demonstrated increased Clock gene expression,
raising the possibility that CH may result from circa-
dian misalignment.
The effects of administration of PACAP on sleep in
humans has not been extensively studied and the
PACAP-effects observed in animals (increase in REM-
sleep) [97] have so far not been reproduced in
humans under the described conditions. This does
not exclude an effect in humans however as there are
many variables that could be changed. As noted pre-
viously, a recent study has implicated a common vari-
ant of the PACAP receptor gene (ADCYAP1R1) [43]
in CH but the results were not replicated in a larger
study [98]. Further, the specifics of how systemically
administered PACAP could regulate circadian rhythms
remains to be elucidated.
Conclusion
PACAP is emerging as an important molecular target
in the pathophysiology of primary headache disorders,
with a particular focus on migraine and CH. It is well
established that there is a clear clinical association
between these conditions and sleep disturbances;
while preclinical studies are beginning to propose
novel mechanisms that underlie these shared etiolo-
gies [9, 89]. It is clear that migraine [50] and CH
[10–12] have a clear rhythmicity, both at the circa-
dian and circannual level and as such future research
should explore both the underlying mechanisms of
this association and the potential for novel transla-
tional lifestyle and pharmacological targets to lighten
the burden of disease.
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There is a need to develop a greater understanding of
the rhythmic changes observed in headaches. For ex-
ample, while PACAP and other molecules such as CGRP
and nitroglycerin can be potent migraine triggers, little is
known about circadian and circannual variability in their
response. Experimentally, individual aspects of circadian
variation in trigeminovascular nociceptive processing,
sleep and autonomic regulation may be studied but it is
ultimately in the combination of our knowledge of these
functions that true progress can be made. Additionally,
while the hypothalamus is emerging as a key modulator of
several primary headache conditions, with respect to cir-
cadian and circannual periodicity we should not lose sight
of the role of peripheral oscillators “local clocks”. The suc-
cessful integration of light entrainment to direct biological
function lies not only with the SCN, but also its alignment
with local oscillators. Finally, the described effect of
PACAP-administration on sleep needs to be studied in
headache patients specifically.
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